Press Releases :: OPKO Health, Inc. (OPK)

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Read the news release

Visit BioReference Health

Year

Category

Feb 10, 2009 12:15 pm EST

OPKO To Present Data on Next Generation Anti-Angiogenic VEGF165b-Sparing siRNA at Association for Research and Vision in Ophthalmology (ARVO 2009) Meeting

Jan 23, 2009 9:13 am EST

OPKO Receives FDA 510(k) Clearance for Spectral OCT SLO Combination Imaging System

Jan 22, 2009 1:49 pm EST

OPKO Health Initiates Clinical Trial of the Aquashunt(TM) to Treat Glaucoma

Dec 4, 2008 9:16 am EST

OPKO Health Announces Completion of Enrollment for Its Phase III Clinical Trial of Bevasiranib for Treatment of AMD

Oct 2, 2008 1:12 pm EDT

OPKO Acquires Worldwide Ophthalmic Rights to Teva's Budesonide for Inflammatory and Allergic Ocular Conditions

Sep 17, 2008 9:00 am EDT

OPKO Health to Present at UBS 2008 Global Life Sciences Conference

Jun 17, 2008 9:35 am EDT

OPKO Health, Inc. Set to Join Russell 3000 Index

Jun 12, 2008 8:00 am EDT

OPKO Acquires Rights to Novel Phase II Agent to Treat Viral Conjunctivitis

Jun 3, 2008 11:51 am EDT

Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye

May 7, 2008 7:45 am EDT

OPKO Health Acquires Company Developing Novel Glaucoma Therapy